CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
29,000
CSL Ltd News & Analysis
etfs
Future Focus: 3 ETFs for Australian equity exposure
personal-finance
Investor Playbook: What these ASX heavyweights reveal about your portfolio
personal-finance
The State of the Australian Investor 2026
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,711.10 | 125.50 | -1.42% |
| CAC 40 | 8,080.74 | 66.09 | -0.81% |
| DAX 40 | 25,463.81 | 272.43 | -1.06% |
| Dow JONES (US) | 49,097.06 | 1,101.11 | -2.19% |
| FTSE 100 | 10,452.68 | 98.49 | -0.93% |
| HKSE | 22,841.62 | 453.13 | -1.95% |
| NASDAQ | 23,879.20 | 550.69 | -2.25% |
| Nikkei 225 | 57,097.59 | 2,346.62 | -3.95% |
| NZX 50 Index | 14,164.76 | 82.49 | -0.58% |
| S&P 500 | 7,175.83 | 147.80 | -2.02% |
| S&P/ASX 200 | 8,609.90 | 120.50 | -1.38% |
| SSE Composite Index | 3,577.08 | 0.54 | -0.02% |